| Arthur S Patterson Phd Inc | |
|
431 S Pine St Sebring FL 33870-3647 | |
| (863) 314-9493 | |
| (863) 382-8672 |
| Full Name | Arthur S Patterson Phd Inc |
|---|---|
| Speciality | Psychologist |
| Location | 431 S Pine St, Sebring, Florida |
| Authorized Official Name and Position | Arthur Patterson (OWNER) |
| Authorized Official Contact | 8633149493 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Arthur S Patterson Phd Inc 431 S Pine St Sebring FL 33870-3647 Ph: (863) 314-9493 | Arthur S Patterson Phd Inc 431 S Pine St Sebring FL 33870-3647 Ph: (863) 314-9493 |
| NPI Number | 1356536122 |
|---|---|
| Provider Enumeration Date | 09/13/2007 |
| Last Update Date | 04/09/2008 |
| Medicare PECOS PAC ID | 1658300926 |
|---|---|
| Medicare Enrollment ID | O20050808000066 |
News Archive
Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests.
Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury.
Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.
A Tallahassee judge ruled Tuesday that a legislative committee did not have the authority to approve a contract regarding prison health care services. According to Businessweek, the plan would privatize health care services in three of Florida's four prison system regions. Circuit Judge John Cooper, who made the decision, said the policy changes must be approved by the full Legislature, rather than just a panel of 14 select legislators.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356536122 | NPI | - | NPPES |
| DE8119 | Other | FL | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PY0003935 (Florida) | Primary |
| Provider Name | Arthur S Patterson |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1982660486 PECOS PAC ID: 3678537768 Enrollment ID: I20041118000123 |
News Archive
Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests.
Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury.
Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.
A Tallahassee judge ruled Tuesday that a legislative committee did not have the authority to approve a contract regarding prison health care services. According to Businessweek, the plan would privatize health care services in three of Florida's four prison system regions. Circuit Judge John Cooper, who made the decision, said the policy changes must be approved by the full Legislature, rather than just a panel of 14 select legislators.
› Verified 7 days ago
News Archive
Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests.
Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury.
Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.
A Tallahassee judge ruled Tuesday that a legislative committee did not have the authority to approve a contract regarding prison health care services. According to Businessweek, the plan would privatize health care services in three of Florida's four prison system regions. Circuit Judge John Cooper, who made the decision, said the policy changes must be approved by the full Legislature, rather than just a panel of 14 select legislators.
› Verified 7 days ago
Drug Free Highlands Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 Lemon Ave, Sebring, FL 33870 Phone: 863-382-2138 Fax: 863-382-2140 | |
Synergy Aba Central Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 326 N Ridgewood Dr Ste A, Sebring, FL 33870 Phone: 863-275-0095 | |
Richard J Sassatelli Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 104 Medical Center Ave, Sebring, FL 33870 Phone: 863-314-0622 Fax: 863-314-9640 | |
Choices Counseling Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32313 Broadway Street Suite #306, Sebring, FL 33870 Phone: 863-257-7454 | |
Best Behavioral Solutions, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 320 N Ridgewood Dr, Sebring, FL 33870 Phone: 863-576-9907 | |
Adventhealth Medical Group Ob Gyn At Sebring Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4200 Sun N Lake Blvd, Sebring, FL 33872 Phone: 863-402-3366 Fax: 863-402-3110 | |
Inner Journey Counseling Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6412 Us Highway 27 S, Sebring, FL 33876 Phone: 863-991-3232 |